Though lung cancer looks promising a partner is now needed.
ApexOnco Front Page
Recent articles
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
The ESMO regular abstract lift reveals first human datasets for several projects.
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
The group toplines a phase 2 win with Alphamedix.
And Treeline and HengRui also get in on the pan-RAS act.
